azacitidine has been researched along with Intellectual Disability in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Delmas, AL; Fields, CR; Jin, B; Liu, X; Peng, J; Qiu, J; Robertson, KD; Soo, HM; Tao, Q; Wu, W; Ying, J | 1 |
Tycko, B | 1 |
1 review(s) available for azacitidine and Intellectual Disability
Article | Year |
---|---|
DNA methylation in genomic imprinting.
Topics: Angelman Syndrome; Animals; Azacitidine; Binding Sites; DNA Methylation; Genetic Diseases, Inborn; Genomic Imprinting; Humans; Intellectual Disability; Methyltransferases; Mice; Prader-Willi Syndrome; Transgenes; Wilms Tumor | 1997 |
1 other study(ies) available for azacitidine and Intellectual Disability
Article | Year |
---|---|
DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function.
Topics: Abnormalities, Multiple; Acetylation; Azacitidine; B-Lymphocytes; Case-Control Studies; Cell Line, Transformed; Cell Transformation, Viral; Cells, Cultured; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Developmental; Genes, Recessive; Histones; Humans; Hydroxamic Acids; Immunologic Deficiency Syndromes; Intellectual Disability; Male; Mutation; Neurons; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Time Factors | 2008 |